Bipartisan drug shortage legislation is gaining traction in the US as coronavirus outbreak begins disrupting the pharmaceutical supply chain: There is a new bill in the House and growing stakeholder support for both the House bill and companion legislation that had been languishing in the Senate.
Drug Shortage Legislation Gains Support As Coronavirus Threatens US Supplies
Coronavirus hysteria sweeps up languishing drug shortage legislation; prospects for new reporting and risk management planning requirements improve.
More from Manufacturing
More from Compliance
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
• By
The UK’s medicines regulator is pressing on with clarifying its expectations on decentralized manufacturing of medicines.
• By
Sponsors should review longstanding agency concepts on consumer-friendly language and claims limitations, along with Office of Prescription Drug Promotion research and enforcement, when applying the 2018 CFL guidance to direct-to-consumer advertising, Sidley Austin’s Cope says.